American Society of Clinical Oncology
![Adcetris Breakthrough: Six-Year Survival Data Reinforce Its Impact in Hodgkin Lymphoma Treatment](https://pharmtales.com/wp-content/uploads/2023/06/Adcetris-Breakthrough_-Six-Year-Survival-Data-Reinforce-Its-Impact-in-Hodgkin-Lymphoma-Treatment.jpg)
Adcetris Breakthrough: Six-Year Survival Data Reinforce Its Impact in Hodgkin Lymphoma Treatment
SG Tylor
Seagen has made a significant announcement regarding the updated U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The update includes ...